High prevalence of raised lipoprotein(a) in patients with refractory angina

Global Cardiology Science and Practice

Volumn 2015, Issue 2, 2015, Pages

  Khan, Tina ^a   Rhodes, Samantha ^a   Pottle, Alison ^a   Banya, Winston ^b   Smith, Robert ^a   Kabir, Tito ^a   Ilsely, Charles ^a   Pennell, Dudley J ^b   Barbir, Mahmoud ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Coronary artery disease; Lipoprotein (a); Refractory angina; Risk factors

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PILOT STUDY; PREVALENCE; REFRACTORY ANGINA PECTORIS; SMOKING; TERTIARY CARE CENTER; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

EID: 85021106354     PISSN: None     EISSN: 23057823     Source Type: Journal    
DOI: 10.5339/gcsp.2015.28     Document Type: Article

References (18)

1. Kim MC, Kini A, Sharma SK. Refractory angina pectoris. Mechanism and therapeutic options. J Am Coll Cardiol. 2002;39(6):923-934.
2. Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, et al. The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002;23(5):355-370.
3. DeJongste MJL, Tio RA, Foreman RD. Chronic therapeutically refractory angina pectoris. Heart 2004;90:225-230.
4. Soran O. Treatment options for refractory angina pectoris: Enhanced external counterpulsation therapy. Curr Treat Options Cardiovasc Med, 2009; 11: 54-60.
5. Manchanda A, Aggarwal A, Aggarwal N, Soran O. Management of refractory angina pectoris. Cardiology Journal. 2011;18(4):343-351.
6. Berg K. A new serum type system in man: the Lp system. ActaPatholMicrobiolScand 1963;59:369-382.
7. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, et al. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444-453.
8. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102(10): 1082-1085.
9. Solanki US, Kumar A. Lipoprotein(a) in essential hypertension patients. Indian Medical Gazette. 2013; 292-295.
10. Erqou S, Kaptoge S, Perry PL, Angelantonio ED, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality. JAMA 2009; 302: 412-423.
11. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31:2844-2853.
12. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361(26):2518-2528.
13. Bambauer R, Olbricht C J, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher Dial. 1997;1:242-248.
14. Stephen Bohl S, Kassner U, Eckardt R, Utz W, Mueller-Nordhorn J, Busjahn A et al. Single Lipoprotein Apheresis Session Improves Cardiac Microvascular Function in Patients with Elevated Lipoprotein(a): Detection by Stress/Rest Perfusion Magnetic Resonance Imaging. TherApher Dial. 2009;13:129-137.
15. HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med 2014; 371:203-212.
16. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials. J Am Coll Cardiol 2014; 63(13):1278-1288.
17. Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, et al. Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein(a) and Lipoprotein (a) in Transgenic Mice. J Am Coll Cardiol 2011; 57:1611-21.
18. Borberg H. Comparison of different Lp(a) elimination techniques: A retrospective evaluation.TransApheresSci 2009; 41:61-65.